Free Trial

Oncobiologics (OTLK) Competitors

Oncobiologics logo
$2.31 -0.10 (-4.15%)
Closing price 07/17/2025 04:00 PM Eastern
Extended Trading
$2.28 -0.04 (-1.52%)
As of 07/17/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OTLK vs. PVLA, ABEO, LFCR, ALDX, VOR, CRVS, SGMT, DBVT, ANNX, and AVTE

Should you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Palvella Therapeutics (PVLA), Abeona Therapeutics (ABEO), Lifecore Biomedical (LFCR), Aldeyra Therapeutics (ALDX), Vor Biopharma (VOR), Corvus Pharmaceuticals (CRVS), Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.

Oncobiologics vs. Its Competitors

Oncobiologics (NASDAQ:OTLK) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Oncobiologics had 2 more articles in the media than Palvella Therapeutics. MarketBeat recorded 2 mentions for Oncobiologics and 0 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.89 beat Oncobiologics' score of 1.08 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Oncobiologics Positive
Palvella Therapeutics Very Positive

Oncobiologics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500.

Palvella Therapeutics has higher revenue and earnings than Oncobiologics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncobiologicsN/AN/A-$75.37M-$0.91-2.54
Palvella Therapeutics$42.81M8.07-$17.43M-$12.10-2.58

Oncobiologics' return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
OncobiologicsN/A N/A -271.12%
Palvella Therapeutics N/A -60.29%-43.30%

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 4.8% of Oncobiologics shares are held by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Oncobiologics currently has a consensus target price of $9.60, suggesting a potential upside of 315.58%. Palvella Therapeutics has a consensus target price of $46.29, suggesting a potential upside of 48.21%. Given Oncobiologics' higher probable upside, equities research analysts clearly believe Oncobiologics is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Palvella Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

Summary

Palvella Therapeutics beats Oncobiologics on 9 of the 15 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OTLK vs. The Competition

MetricOncobiologicsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$80.90M$2.94B$5.57B$9.34B
Dividend YieldN/A2.45%3.80%4.06%
P/E Ratio-2.5420.2928.1019.86
Price / SalesN/A302.32441.4199.96
Price / CashN/A43.1635.8457.94
Price / Book-0.757.838.265.67
Net Income-$75.37M-$55.11M$3.24B$257.80M
7 Day Performance11.59%3.21%1.48%1.87%
1 Month Performance37.50%12.86%8.07%10.92%
1 Year Performance-71.52%5.06%30.29%18.51%

Oncobiologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OTLK
Oncobiologics
2.5356 of 5 stars
$2.31
-4.1%
$9.60
+315.6%
-74.2%$80.90MN/A-2.5420Positive News
PVLA
Palvella Therapeutics
2.5393 of 5 stars
$27.55
+4.1%
$46.29
+68.0%
N/A$304.59MN/A-2.28N/APositive News
ABEO
Abeona Therapeutics
3.7509 of 5 stars
$5.92
+3.1%
$19.25
+225.2%
+22.3%$302.87M$3.50M-4.6690
LFCR
Lifecore Biomedical
1.3528 of 5 stars
$8.17
-1.6%
$8.00
-2.1%
+38.1%$302.49M$130.31M-5.63690News Coverage
ALDX
Aldeyra Therapeutics
2.385 of 5 stars
$5.01
+7.7%
$9.50
+89.6%
+23.6%$300.08MN/A-5.1610News Coverage
VOR
Vor Biopharma
3.5305 of 5 stars
$2.39
-4.4%
$5.63
+135.5%
+138.8%$298.65MN/A-1.45140
CRVS
Corvus Pharmaceuticals
2.8704 of 5 stars
$4.35
+5.1%
$15.00
+244.8%
+95.9%$296.54MN/A-4.4430Positive News
SGMT
Sagimet Biosciences
2.3509 of 5 stars
$9.46
-0.1%
$26.60
+181.2%
+180.9%$290.14M$2M-5.388News Coverage
DBVT
DBV Technologies
3.858 of 5 stars
$10.58
-2.1%
$14.75
+39.5%
+142.8%$289.68M$4.15M-2.1580Positive News
ANNX
Annexon
2.2533 of 5 stars
$2.61
+1.2%
$12.50
+378.9%
-60.1%$286.34MN/A-2.2160
AVTE
Aerovate Therapeutics
N/A$9.82
-6.7%
N/A-86.7%$284.63MN/A-3.2820High Trading Volume

Related Companies and Tools


This page (NASDAQ:OTLK) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners